Bausch + Lomb

Using OCTA in optometric practice
Using OCTA in optometric practiceBy using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Understanding the conundrum of conjunctivochalasisConjunctival chalasis, or conjunctivochalasis (Cch), is a commonly observed condition in our everyday patient care experiences. Because it is so common, and because a majority of patients are asymptomatic, optometrists seldom feel the need treat.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
B+L next-generation surgical platform features advanced retina capabilities
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Phaco technology evolves over timeFifty years after the idea for phacoemulsification came to Charles Kelman, MD, few would have predicted that surgical platforms would evolve to where they are today.
Next-generation phaco system design improves stability, reduces energyLos Angeles ophthalmologist Mitchell Shultz, MD, shares some of his clinical experience with a next-generation phacoemulsification platform (Stellaris Elite, Bausch + Lomb). The new platform received 510(k) clearance from the FDA in April.
5 reasons to upgrade patients from monovision to multifocalsMany optometrists use the “if it aint broke, don’t fix it” excuse for not fitting multifocals. It is time for ODs to get comfortable with multifocal contact lenses and the opportunity they provide our practices as well as the ability they give us to meet modern patient demands.
10 tips to enhance scleral contact lens success
10 tips to enhance scleral contact lens successImprove your scleral fitting skills and your patients’ quality of life